Humana Holder Read: Dodge & Cox at 1.08% Portfolio Bet

Humana has been one of the most challenging managed-care stories of 2024-2026. The company's Medicare Advantage franchise, historically a multi-decade compounder, faced material profitability pressure after the 2024 v28 risk-adjustment model changes that compressed plan reimbursement. The stock dropped from $570 to $230 across the 2024 reset cycle and has been working through the operational and pricing recovery since. The 13F holder book reflects this stress — active institutional managers mostly reduced or eliminated positions. One firm stood out as a meaningful active overweight: Dodge & Cox holds Humana at $1.97 billion and 1.08% portfolio weight — the largest non-passive active conviction in the book. The position represents the Dodge & Cox value-discipline call on managed-care franchise recovery.

Dodge & Cox is one of the longest-running US deep-value institutional managers (founded 1930). The firm's stated philosophy emphasizes price discipline relative to intrinsic value, multi-year holding periods, and contrarian positioning into stress cycles. The HUM concentration fits this framework cleanly — concentrated overweight into the post-2024-stress recovery cycle at compressed multiples.

The 2024 Medicare Advantage repricing

The Medicare Advantage business model depends on risk-adjustment payments from CMS that compensate insurers for enrolling sicker beneficiaries. The 2024 v28 model changes meaningfully tightened the risk-coding-to-payment relationship, removing approximately $9-12 billion of industry-wide annual reimbursement. Humana's revenue mix is heavily Medicare-Advantage-weighted (over 50% of revenue), making it the largest single beneficiary-of-the-prior-system and the largest single relative loser under v28.

The impact on Humana operations:

• 2024 medical-cost ratio expanded sharply as Humana absorbed reimbursement compression on existing membership.
• 2025 saw operational restructuring including plan-level closures, benefit reductions, and provider-network adjustments.
• 2026 guidance reflects ongoing operational normalization plus repricing benefits as v28 is fully reflected in benefit-design and pricing.

The Dodge & Cox value-discipline thesis

The Dodge & Cox 1.08% portfolio concentration on HUM ($1.97 billion) represents a multi-step value-discipline thesis:

1. Franchise durability post-stress. Humana remains the second-largest pure Medicare Advantage insurer (behind UnitedHealth's Optum). The franchise economics — including specialty pharmacy CenterWell, primary-care clinic CenterWell, and home-health Onehome — provide multi-year operational levers despite the 2024 reset.
2. Multiple compression overshoot. HUM traded at 8-10x forward P/E in 2025-2026 versus the historical 15-20x range. Dodge & Cox views this as multiple-compression overshoot rather than structural franchise decline.
3. Operational recovery timeline. 2026-2027 represents the expected operational normalization window as v28 reimbursement is fully reflected in pricing. The Dodge & Cox view captures the operational-recovery cycle.

The 1,400-institution holder book

HUM's holder book carries the standard passive index sleeve plus the Dodge & Cox concentration:

• Dodge & Cox: $1.97 billion, 1.08% portfolio — the value-discipline overweight.
• BlackRock: $1.77 billion, 0.03% portfolio — slight underweight.
• State Street: $1.40 billion, 0.05% portfolio.
• Vanguard Capital Management: $1.36 billion, 0.03% portfolio.
• Vanguard Portfolio Management: $1.01 billion, 0.05% portfolio.

Note the small absolute dollar values — HUM's market cap has compressed materially from its 2023 peak ($85 billion) to the 2026 mid-$30 billion range. The institutional positions reflect both reduced dollar exposure and reduced active conviction.

What's notably absent

1. No Berkshire position. Buffett held Aetna briefly during early-2000s healthcare-stress cycles but has structurally avoided managed-care since. The Berkshire absence means no value-discipline anchor beyond Dodge & Cox.
2. No activist 13D filings. Despite the multi-year operational stress and capital-allocation criticism, no external activist has filed against Humana. CEO Jim Rechtin (transitioned in late 2024) runs the strategic plan without governance pressure.
3. Limited specialist healthcare overweights. Capital World, Wellington, FMR, and other large healthcare-focused active managers have not built concentrated overweights at HUM through the recovery cycle.

What to track

1. Humana Q2 2026 earnings (late July). 2026 medical-cost ratio guidance, member retention through plan-level benefit changes, and CenterWell platform growth.
2. CMS Medicare Advantage policy updates. Any v28-model adjustment, benchmark-rate update, or risk-coding-rule change directly affects the recovery trajectory.
3. Dodge & Cox Q2 2026 13F (due August 14, 2026). Whether the 1.08% HUM position holds, expands, or trims. Track via the institutional signals feed.
4. Cybersecurity threat trajectory. Healthcare payors face elevated AI-cyber threat exposure. Watch for any HUM-specific or sector-wide cyber incidents.

Humana's holder book carries Dodge & Cox's 1.08% portfolio concentration as the cleanest active value-discipline conviction signal on managed-care franchise recovery. For more on identifying deep-value contrarian active positions, see our operational cycle reading guide.

Source: SEC Form 13F-HR filings for Q1 2026 period ending 2026-03-31, accession listings at Humana Inc. SEC filer index.